If an appropriate concentration of heparin is added to whole blood the clotting time is prolonged, due presumably to the inactivation of C.F. by heparin: " available " heparin disappears during clotting and none is found in the serum. The interactions summarized above probably account for these findings. The disappearance of available heparin would also account for the normal thrombin generation and prothrombin consumption observed when heparinized blood clots.
Some properties of P.L.A.S. are reported and its possible role in normal coagulation is considered. Heparin is known to become attached preferentially to one protein rather than another. Some plasma and serum fractions can be arranged in order of their increasing affinity for heparin thus: f Lipoproteins < thrombin clotting system < C.F. < platelet protein < protamine sulphate.
Heparin is used extensively in clinical medicine. Mast cells contain heparin, and these cells have been described in the subendothelial layers of the blood vessels (McGovern, 1955) : thus heparin may have some physiological anticoagulant role.
Precise knowledge of its anticoagulant action may therefore be of practical importance. The antithrombic action of heparin has long been known, but its action on the earlier stages of coagulation is less clear (e.g., Walton, 1955) . Biggs, Douglas, and Macfarlane (1953) showed that heparin depresses intrinsic thromboplastin formation. Douglas (1956) suggested that heparin inhibits clotting early in the coagulation process. O'Brien (1958a) claimed that heparin inactivated Christmas factor (C.F.). Shanberge, Barlas, and Regan (1958) claim that the heparin antagonist, protamine sulphate, also inactivates C.F., although Hougie (1958) does not agree. The antiheparin activity of platelets was reported by van Creveld and Paulssen (1951) . Garrett and Klein (1957) showed that lipid-extracted platelet material, presumably a protein, contains the antiheparin activity, while the lipid extract contains the clot-accelerating lipid of platelets.
Methods
Native Platelet-rich Plasma.-This was prepared by taking v,enous blood by syringe and centrifuging 5 ml. lots at 500 r.p.m. for five minutes and collecting the supernatant. This was used at once or stored on ice. Silicone-coated apparatus was used throughout.
Native Platelet-poor Plasma.-This was prepared by centrifuging native blood at 4,000 r.p.m. for seven minutes and removing two-thirds of the plasma and re-centrifuging this. Silicone-coated apparatus was used throughout.
Citrated Plasma. This, platelet-rich or plateletpoor, was prepared as above, but the blood was first mixed with one-tenth of its volume of 3.8°,' trisodium citrate solution in water.
Normal Serum.-Normal serum was prepared from normal blood by allowing it to clot in contact with glass for at least one hour and centrifuging at 4,000 r.p.m. for 10 minutes and collecting the supernatant.
Platelet-poor Serum. (Biggs and Douglas, 1953) in which normal dilute absorbed plasma and cephalin or platelets were used and the test serum diluted 1 in 10 was added.
In some situations the shortening of the clotting time of plasma from a patient suffering from Christmas disease was used.
Tests for Platelet-like Activity of Serum
The test for this activity, reported in 1955 (O'Brien), was copied exactly. Equal volumes of the serum under investigation and of normal citrated plateletpoor plasma are mixed and placed in a water-bath at 37°C. for one minute and then recalcified. This tube is watched till it clots, and thereafter 0.1 ml. aliquots are transferred at minute intervals to a series of tubes containing 0.4 ml. of fibrinogen solution. The clotting time of fibrinogen measures the concentration of thrombin in the original mixture at the time the subsample was taken. The shortest fibrinogen clotting time, measuring the maximum thrombin concentration, is directly related to the P.L.A.S. content of the serum.
Tests for Cephalin Activity of Platelets.-4a) The thrombin generation test was carried out exactly as in the estimation of P.L.A.S., but with the substitution of the platelets under investigation for the serum.
(b) The Stypven time of platelet-poor plasma is greatly accelerated by the addition of isolated cephalins or by cephalin bound in a macromolecule such as platelet protein (O'Brien, 1958b) . Equal volumes of plasma, dilute Russell viper venom, and the platelets under test were recalcified and the clotting time recorded.
Results
Action of Heparin on Christmas Factor.-This was studied using the thromboplastin generation test (Table I , part 1). It may be concluded that heparin in the appropriate strength prevents the formation of thromboplastin but does not inactivate formed thromboplastin, and that heparin in the concentration used does not affect the clotting system in the subsample tubes. than those containing none. It may be concluded that plasma C.F. had inactivated some heparin and that serum C.F. inactivated more heparin than plasma C.F. This might be due to the fact that C.F. in serum is a Ca-C.F. complex (Bergsagel, 1955) . Normal platelet-poor serum was accordingly decalcified by mixing it with one tenth of its volume of 3.8 % trisodium citrate for 24 hours. This citrated serum was compared with another aliquot of the same serum citrated immediately before testing (Table II C ). The decalcified serum apparently inactivated considerably less heparin. Thus the ability of serum C.F. to inactivate more heparin than plasma C.F. is probably related to the fact that serum C.F. is a Ca-C.F. complex.
Serum from platelet-poor Christmas disease blood contains factor VII: absorption of this serum will remove it. Neither of these two kinds of sera inactivated appreciable quantities of heparin. It is concluded that factor VII does not inactivate a demonstrable amount of heparin.
Action of Platelets on Heparin.-Platelet-rich and platelet-poor native plasmas inactivated the same small amount of heparin. Thus intact platelets do not inactivate heparin but fragmented platelets (Table III To one volume of the material in column one was added one volume of saline or heparin in the strength indicated and one volume of fibrinogen. Thrombin was then added and the clotting time in seconds is recorded.
findings are fully compatible with the previous reports of, for example, Wolf (1956) and Rapaport and Ames (1957) .
Action of Heparin on Platelets.-The cephalin activity of platelets in platelet-rich plasma was measured in the thrombin generation test. To an aliquot of this plasma was added sufficient heparin, e.g., 0.5 unit/ml., together with powdered glass so that the clotting time was not much altered. Clotting of Normal Blood.-Two rows of tubes were prepared containing 0.1 ml. of two appropriate strengths of heparin, e.g., 0.5 u./ml. and 0.25 u./ml. To all tubes was added 0.4 ml. of fibrinogen solution. Twenty millilitres of freshly drawn blood was placed in a test tube in the water-bath and allowed to clot and at appropriate intervals 2 ml. aliquots were removed, citrated, and centrifuged: one hour later 0.1 ml. of each aliquot was transferred to the tubes containing the fibrinogen and heparin and mixed, 0.1 ml. of a strong thrombin solution was added, and the clotting times recorded (Table IV) . Initially the blood inactivated very little heparin since long thrombin clotting At the times indicated 2 ml. of blood was removed and citrated:
one hour later 0 1 ml. of the centrifuged plasma was added to 0-4 ml.
of fibrinogen and 0-1 ml. of saline or beparin and thrombin added.
-Indicates first visible clotting.
times were recorded. The ability of the blood to inactivate heparin increased slightly up to the time of the appearance of the first signs of clotting in the blood and thereafter increased rapidly and markedly during the next five minutes.
(2) Disappearance of Heparin Activity during Clotting of Hoparinized Blood.-Twenty millilitres of blood from either heparinized volunteers, e.g., 2,000 u. heparin injected i.v. five minutes before bleeding, or normal blood subsequently heparinized, e.g., 0.2 u. / ml. blood, was placed in a beaker at 370 C. and powdered glass added to accelerate the clotting time.
The blood usually clotted in about 15 minutes. In each run several of the following tests were carried out on subsamples removed from the beaker at appropriate intervals up to one hour.
(a) A vailable platelet cephalin was monitored up to the time of clotting only (thereafter the platelets are largely caught up in the clot) by serially removing 1 ml. subsamples from the beaker, citrating, and estimating the Stypven time one hour later. This test was shown to be unaffected by the concentration of free heparin present.
(bl) Thrombin formation was monitored by subsampling 0.1 ml. amounts into 0.4 ml. of fibrinogen solution.
(b2) Thrombin generation could also be indirectly studied by doing two-stage prothrombin tests on the citrated subsamples of the blood one hour later.
(c) The Formation of P.L.A.S.-Amounts, each of 1 ml., were removed and citrated. They were centrifuged and (usually) absorbed to remove platelet activity and any free heparin, and one hour later they were tested for P.L.A.S. as previously described.
(dl) The neutralization of heparin by the blood in the beaker was monitored by subsampling into a fibrinogen solution, adding a strong solution of thrombin and estimating the thrombin clotting time.
(d2) The neutralization of heparin was further studied by estimating the clotting time of plateletpoor citrated normal plasma to which was added hour-old citrated subsamples of the blood from the beaker.
Similar appropriate observations were carried out on unheparinized blood.
The rate of formation and the approximate concentrations of' platelet cephalin, of thrombin, and of P.L.A.S. were not appreciably influenced by the initial presence of heparin in the blood (Fig. 1) The results of the foregoing experiments can also be considered from the point of view of the relative ability of the various coagulation factors to bind heparin. Heparin in small quantities added to plasma is bound largely by the f lipoproteins (Bernfeld, Donahue, and Berkowitz, 1957; Nikkili, 1953) , yet this heparin is " available " to delay the thrombin clotting system. This latter system must have a greater affinity for heparin than the ,B lipoproteins. Conversely, heparin bound to C.F. does not influence the thrombin clotting system. The affinity of heparin for C.F. must be greater than its affinity for the relevant protein involved in the thrombin clotting system. The addition of platelet protein to the heparin-C.F. complex liberates C.F. activity, indicating that the affinity of heparin for platelets is greater than that for C.F. And the ability of protamine sulphate to reverse the heparin effect on all these factors indicates that the attraction between heparin and protamine sulphate is greatest of all. This conclusion may be expressed diagrammatically:
